DUBLIN--(http://www.researchandmarkets.com/research/w5rzjx/gastric_cancer) has announced the addition of Decision Resources, Inc's new report "Gastric Cancer" to their offering.)--Research and Markets (
Gastric cancer (GC) is one of the most common malignancies in terms of incidence and the second most common cause of cancer-related death worldwide. Japan has the highest incidence of GC among the markets under study, presenting a potentially high commercial reward.
The approval of trastuzumab (Roche/Genentech/Chugai's Herceptin) for the first-line treatment of HER2-positive GC is a significant milestone that marks the beginning of a new era for targeted therapy treatment in GC.
However, there is a high unmet need for more therapeutic options. The launch of three premium-priced targeted agents by 2020 will address this need, almost doubling sales and dramatically impacting the GC market.
Key Topics Covered:
What are the key parameters of the gastric cancer market?
What factors are driving the market for gastric cancer therapies?
What factors are constraining the market for gastric cancer therapies?
What are the drug development activities of note in gastric cancer?
What do the experts say?
What key challenges and opportunities remain?
1 Etiology and Pathophysiology
2 Epidemiology and Patient Populations
3 Current Therapies and Medical Practice
4 Unmet Needs
5 Emerging Therapies
6 Market Outlook
Tables and Figures
For more information visit http://www.researchandmarkets.com/research/w5rzjx/gastric_cancer
Source: Decision Resources, Inc